Mechanisms of complement activation and effects of C1-inhibitor on the meconium-induced inflammatory reaction in human cord blood

Molecular Immunology

Volumn 46, Issue 4, 2009, Pages 688-694

  Salvesen, Bodil ^a   Nielsen, Erik W ^b   Harboe, Morten ^a   Saugstad, Ola D ^a   Mollnes, Tom E ^a  

^a UNIVERSITY OF OSLO   (Norway)

^b NORDLAND HOSPITAL   (Norway)

Author keywords

C1 inhibitor; Complement system; Cord blood; Cytokines; Inflammation; Meconium

Indexed keywords

ALBUMIN; ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; CETOR; COMPLEMENT COMPONENT C1S INHIBITOR; COMPLEMENT COMPONENT C4D; CYTOKINE; EOTAXIN; FIBROBLAST GROWTH FACTOR; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LEPIRUDIN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MANNOSE BINDING LECTIN; MONOCLONAL ANTIBODY; MONOCYTE CHEMOTACTIC PROTEIN 1; PLATELET DERIVED GROWTH FACTOR BB; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTICOAGULATION; ARTICLE; COMPLEMENT ACTIVATION; DONOR; DOSE RESPONSE; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; INCUBATION TIME; INFLAMMATION; MECONIUM; NEWBORN; PRIORITY JOURNAL; UMBILICAL CORD BLOOD;

COMPLEMENT ACTIVATION; COMPLEMENT C1; COMPLEMENT C1 INHIBITOR PROTEIN; COMPLEMENT PATHWAY, ALTERNATIVE; CYTOKINES; FETAL BLOOD; HUMANS; INFANT, NEWBORN; INFLAMMATION; MECONIUM; MECONIUM ASPIRATION SYNDROME;

EID: 58249098534     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molimm.2008.09.001     Document Type: Article

References (31)

1. Brekke O.L., Christiansen D., Fure H., Fung M., and Mollnes T.E. The role of complement C3 opsonization, C5a receptor, and CD14 in E. coli-induced up-regulation of granulocyte and monocyte CD11b/CD18 (CR3), phagocytosis, and oxidative burst in human whole blood. J. Leukocyte Biol. 81 (2007) 1404-1413
2. Cai S., Dole V.S., Bergmeier W., Scafidi J., Feng H., Wagner D.D., and Davis III A.E. A direct role for C1 inhibitor in regulation of leukocyte adhesion. J. Immunol. 174 (2005) 6462-6466
3. Caliezi C., Wuillemin W.A., Zeerleder S., Redondo M., Eisele B., and Hack C.E. C1-esterase inhibitor: an anti-inflammatory agent and its potential use in the treatment of diseases other than hereditary angioedema. Pharmacol. Rev. 52 (2000) 91-112
4. Castellheim A., Lindenskov P.H., Pharo A., Fung M., Saugstad O.D., and Mollnes T.E. Meconium is a potent activator of complement in human serum and in piglets. Pediatr. Res. 55 (2004) 310-318
5. Cicardi M., Zingale L., Zanichelli A., Pappalardo E., and Cicardi B. C1 inhibitor: molecular and clinical aspects. Springer Semin. Immunopathol. 27 (2005) 286-298
6. Cleary G.M., and Wiswell T.E. Meconium-stained amniotic fluid and the meconium aspiration syndrome. An update. Pediatr. Clin. N. Am. 45 (1998) 511-529
7. Collard C.D., Vakeva A., Morrissey M.A., Agah A., Rollins S.A., Reenstra W.R., Buras J.A., Meri S., and Stahl G.L. Complement activation after oxidative stress: role of the lectin complement pathway. Am. J. Pathol. 156 (2000) 1549-1556
8. Cooper N.R. The classical complement pathway: activation and regulation of the first complement component. Adv. Immunol. 37 (1985) 151-216
9. Davis III A.E. Biological effects of C1 inhibitor. Drug News Perspect. 17 (2004) 439-446
10. Davis III A.E., Cai S., and Liu D. C1 inhibitor: biologic activities that are independent of protease inhibition. Immunobiology 212 (2007) 313-323
11. Fure H., Nielsen E.W., Hack C.E., and Mollnes T.E. A neoepitope-based enzyme immunoassay for quantification of C1-inhibitor in complex with C1r and C1s. Scand. J. Immunol. 46 (1997) 553-557
12. Harboe M., Garred P., Borgen M.S., Stahl G.L., Roos A., and Mollnes T.E. Design of a complement mannose-binding lectin pathway-specific activation system applicable at low serum dilutions. Clin. Exp. Immunol. 144 (2006) 512-520
13. Harboe M., and Mollnes T.E. The alternative complement pathway revisited. J. Cell. Mol. Med. (2008)
14. Harboe M., Ulvund G., Vien L., Fung M., and Mollnes T.E. The quantitative role of alternative pathway amplification in classical pathway induced terminal complement activation. Clin. Exp. Immunol. 138 (2004) 439-446
15. Jansen P.M., Eisele B., de I J., Chang A., Delvos U., Taylor Jr. F.B., and Hack C.E. Effect of C1 inhibitor on inflammatory and physiologic response patterns in primates suffering from lethal septic shock. J. Immunol. 160 (1998) 475-484
16. Jiang H., Wagner E., Zhang H., and Frank M.M. Complement 1 inhibitor is a regulator of the alternative complement pathway. J. Exp. Med. 194 (2001) 1609-1616
17. Kirschfink M., and Mollnes T.E. C1-inhibitor: an anti-inflammatory reagent with therapeutic potential. Expert Opin. Pharmacother. 2 (2001) 1073-1083
18. Levy R.M., Prince J.M., Yang R., Mollen K.P., Liao H., Watson G.A., Fink M.P., Vodovotz Y., and Billiar T.R. Systemic inflammation and remote organ damage following bilateral femur fracture requires toll-like receptor 4. Am. J. Physiol. Regul. Integr. Comp. Physiol. 291 (2006) R970-R976
19. Lindenskov P.H., Castellheim A., Aamodt G., Saugstad O.D., and Mollnes T.E. Complement activation reflects severity of meconium aspiration syndrome in newborn pigs. Pediatr. Res. 56 (2004) 810-817
20. Liu D., Cai S., Gu X., Scafidi J., Wu X., and Davis III A.E. C1 inhibitor prevents endotoxin shock via a direct interaction with lipopolysaccharide. J. Immunol. 171 (2003) 2594-2601
21. Liu D., Lu F., Qin G., Fernandes S.M., Li J., and Davis III A.E. C1 inhibitor-mediated protection from sepsis. J. Immunol. 179 (2007) 3966-3972
22. Mollnes T.E., Brekke O.L., Fung M., Fure H., Christiansen D., Bergseth G., Videm V., Lappegard K.T., Kohl J., and Lambris J.D. Essential role of the C5a receptor in E. coli-induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation. Blood 100 (2002) 1869-1877
23. Mollnes T.E., Lea T., Froland S.S., and Harboe M. Quantification of the terminal complement complex in human plasma by an enzyme-linked immunosorbent assay based on monoclonal antibodies against a neoantigen of the complex. Scand. J. Immunol. 22 (1985) 197-202
24. Mollnes T.E., Lea T., and Harboe M. Detection and quantification of the terminal C5b-9 complex of human complement by a sensitive enzyme-linked immunosorbent assay. Scand. J. Immunol. 20 (1984) 157-166
25. Okazaki K., Kondo M., Kato M., Kakinuma R., Nishida A., Noda M., Taniguchi K., and Kimura H. Serum cytokine and chemokine profiles in neonates with meconium aspiration syndrome. Pediatrics 121 (2008) e748-e753
26. Petersen S.V., Thiel S., Jensen L., Vorup-Jensen T., Koch C., and Jensenius J.C. Control of the classical and the MBL pathway of complement activation. Mol. Immunol. 37 (2000) 803-811
27. Salvesen B., Fung M., Saugstad O.D., and Mollnes T.E. Role of complement and CD14 in meconium-induced cytokine formation. Pediatrics 121 (2008) e496-e505
28. Sprong T., Moller A.S., Bjerre A., Wedege E., Kierulf P., van der Meer J.W., Brandtzaeg P., van D.M., and Mollnes T.E. Complement activation and complement-dependent inflammation by neisseria meningitidis are independent of lipopolysaccharide. Infect. Immunol. 72 (2004) 3344-3349
29. Zeerleder S., Caliezi C., van M.G., Eerenberg-Belmer A., Sulzer I., Hack C.E., and Wuillemin W.A. Administration of C1 inhibitor reduces neutrophil activation in patients with sepsis. Clin. Diag. Lab. Immunol. 10 (2003) 529-535
30. Zhang H., Li J., Barrington R.A., Liang G., Qin G., and Liu D.X. An anti-endotoxin peptide that generates from the amino-terminal domain of complement regulatory protein C1 inhibitor. Biochem. Biophys. Res. Commun. 359 (2007) 285-291
31. Zhao H., Wakamiya N., Suzuki Y., Hamonko M.T., and Stahl G.L. Identification of human mannose binding lectin (MBL) recognition sites for novel inhibitory antibodies. Hybrid Hybridom. 21 (2002) 25-36